TransMedics Group (NASDAQ: TMDX) reported Q2 EPS of ($0.39), $0.11 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $8.2 million versus the consensus estimate of $7.8 million.

Cash, cash equivalents and marketable securities were $112.2 million as of June 30, 2021.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.